Browsing by Author JASINGHE VIRAJ JANAKAKUMARA

Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)
2008ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograftJasinghe, V.J. ; Xie, Z. ; Zhou, J. ; Khng, J.; Poon, L.-F. ; Senthilnathan, P. ; Chen, C.-S. ; Albert, D.H.; Davidsen, S.K.
2009Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AMLZhou, J. ; Bi, C.; Janakakumara, J.V. ; Liu, S.-C.; Chng, W.-J.; Tay, K.-G. ; Poon, L.-F. ; Xie, Z. ; Palaniyandi, S. ; Chen, C.-S. ; Yu, H. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
2009Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AMLZhou, J. ; Bi, C.; Janakakumara, J.V. ; Liu, S.-C.; Chng, W.-J. ; Tay, K.-G. ; Poon, L.-F. ; Xie, Z. ; Palaniyandi, S. ; Chen, C.-S. ; Yu, H. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
2008In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptorZhou, J. ; Khng, J.; Jasinghe, V.J. ; Bi, C.; Poon, L.F. ; Xie, Z. ; Chen, C.-S. ; Neo, C.H.S.; Pan, M.; Yu, H. ; Yeoh, A.E.-J.; Lu, Y. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
2008In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptorZhou, J. ; Khng, J.; Jasinghe, V.J. ; Bi, C.; Poon, L.F. ; Xie, Z. ; Chen, C.-S. ; Neo, C.H.S.; Pan, M.; Yu, H. ; Yeoh, A.E.-J. ; Lu, Y. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
2008Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasionXie, Z. ; Choong, P.F. ; Poon, L.F. ; Zhou, J. ; Khng, J. ; Jasinghe, V.J. ; Palaniyandi, S. ; Chen, C.-S. 
2006Vitamin D2from irradiated mushrooms significantly increases femur bone mineral density in ratsJasinghe, V.J. ; Perera, C.O. ; Barlow, P.J.